Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2014 12:05 ET | Source: DBV Technologies

Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV's EPIT(TM) Disease Modifying Effect

BAGNEUX, France, June 10, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, presented today...
April 16, 2014 01:37 ET | Source: DBV Technologies

DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPIT) with Viaskin(R) at the French Congress of Allergy

Dr. Thierry Bourrier and Pr. Christophe Dupont present abstract showing that a peanut-allergic child from the ARACHILD study had a sustained desensitization even after one year off treatment...
April 15, 2014 01:33 ET | Source: DBV Technologies

DBV Technologies : DBV Technologies Announces Topline Financial Results for First Three Months 2014

BAGNEUX, France, April 15, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new reference in the treatment of allergy, announced today its...
March 04, 2014 12:05 ET | Source: DBV Technologies

Presentation and Publication of Research at AAAAI Demonstrates EPIT(TM)'s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect

BAGNEUX, France, March 4, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, today announced that...
October 24, 2013 02:14 ET | Source: DBV Technologies

NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies' Viaskin(R) Peanut in the treatment of peanut allergy

Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV' team CoFAR6 study will help to better...
October 22, 2013 12:33 ET | Source: DBV Technologies

DBV Technologies Forms Research Collaboration with Inserm to Develop Viaskin(R) for Refractory Hemophilia A Disease

BAGNEUX, France, Oct. 22, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext:DBV) (ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, announced today that it...
October 15, 2013 02:49 ET | Source: DBV Technologies

DBV Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on Viaskin(R) Peanut

BAGNEUX, France, Oct. 15, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext:DBV) (ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its...